New Antibiotic Access Expands in Latin America
Patients in nine countries gain a new option for treating resistant bacterial infections.
Updated on Oct. 30, 2026 in Diseases — General
Live Poll
Should pharmaceutical companies prioritize expanding access to newer medical treatments in developing regions?
Orchid Pharma has entered a licensing agreement with Laboratorio Libra to bring the antibiotic Exblifep to nine Latin American countries. This move aims to expand regional access to the treatment for complicated urinary tract infections and bacterial pneumonia.
Why it matters
Expanding access to Exblifep, a combination of cefepime and enmetazobactam, provides a new option for treating specific bacterial infections caused by Gram-negative pathogens. This partnership addresses a regional need for advanced antibiotics to help combat the growing threat of antimicrobial resistance.
The agreement grants Laboratorio Libra exclusive rights to register, import, and market Exblifep across nine countries following the drug's approval by the FDA and EMA. While the partnership targets a $80 million commercial opportunity over 10 years, local availability remains subject to regulatory review.
The players
Orchid Pharma
An India-based pharmaceutical company that manufactures and supplies antibiotic medications.
Laboratorio Libra
A Uruguay-based laboratory founded in 1961 that develops and distributes pharmaceutical products in Latin America.
The details
Exblifep works by combining cefepime, a cephalosporin antibiotic, with enmetazobactam, a beta-lactamase inhibitor. This combination allows the drug to overcome resistance mechanisms often utilized by Gram-negative bacteria that would otherwise render standard antibiotics ineffective. Under the new agreement, Orchid Pharma manages the manufacturing and supply of the medication.
Timeline
1961: Laboratorio Libra was founded in Uruguay.
First 10 years: Estimated timeframe for an US$80 million commercial opportunity.
Health Landscape
This agreement marks an effort to distribute advanced antibiotic therapies to regions where specific treatment options for resistant infections have been limited. It aligns with global strategies to ensure that newer, high-potency antibiotics reach populations facing complex Gram-negative infections.
Patients with complex infections in the affected Latin American countries may soon have broader access to this antibiotic option. If you or a family member are being treated for persistent urinary or respiratory infections, discuss the latest local treatment guidelines with your physician.
The takeaway
The addition of new antibiotic options helps doctors better target resistant Gram-negative bacteria that do not respond to common medications. Always consult your healthcare provider regarding the most effective and appropriate antibiotics for your specific type of infection.
Further reading
Learn more about evolving antibiotic treatment standards in our Diseases — General section.
Source note: This article includes information reported by Themachinemaker.
Live Poll
Should pharmaceutical companies prioritize expanding access to newer medical treatments in developing regions?
